Trial
NCT02373241
Preventing Sickle Cell Kidney Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Alabama at Birmingham
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Condition
Anemia, Sickle Cell
Intervention
Losartan
Why stopped
Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-03